Please find attached Intimation regarding acquisition of stake by a wholly owned subsidiary company.
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 02 Jun 2026, 05:38 PM IST · BSE ID: 6528d477-ea37-42cd-b158-716b48ae53ad
View Original BSE Filing (PDF)
💡
In Simple Terms
Mankind Pharma's subsidiary bought the final 10% of Upakarma Ayurveda for ₹75 Lakhs, making it a fully owned company.
🤖 AI Summary
- Mankind Lifesciences Private Limited acquired the remaining 10% stake in Upakarma Ayurveda Private Limited.
- The acquisition of 10% stake was completed for a cash consideration of ₹75 Lakhs, payable in two tranches.
- Upakarma Ayurveda is now a 100% wholly owned step-down subsidiary of Mankind Pharma Limited.
- Upakarma Ayurveda, engaged in ayurvedic products, recorded a turnover of ₹18.02 Crores as on March 31, 2026.
- The acquisition aims to achieve better operational efficiencies through streamlined processes.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Cost of Acquisition (remaining 10% stake)
₹75 Lakhs
Upakarma Authorized Share Capital
₹2.00 Crores
Upakarma Paid-up Share Capital
₹1.80 Crores
Upakarma Turnover (as on March 31, 2026)
₹18.02 Crores
Upakarma Turnover (2024-25)
₹13.06 Crores
Upakarma Turnover (2023-24)
₹23.04 Crores
🏢 How This Affects the Company
This acquisition integrates Upakarma Ayurveda fully into Mankind Pharma's structure, enhancing its presence in the ayurvedic, herbal, and nutraceutical product market in India.
The cash consideration of ₹75 Lakhs impacts cash reserves. Upakarma's turnover of ₹18.02 Crores (FY26) will be fully consolidated into the parent company's financials.
Full ownership of Upakarma Ayurveda enables Mankind Pharma to achieve better operational efficiencies through streamlined processes and unified management.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders as this is an operational acquisition by a subsidiary.
👤
Who Is Affected
Shareholders of Mankind Pharma Limited are indirectly affected as their company now fully owns Upakarma Ayurveda, which had a turnover of ₹18.02 Crores in FY26.
🔍
Management Signal
The acquisition signals management's intent to consolidate and streamline operations within its existing portfolio, specifically in the ayurvedic and nutraceutical segments.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Mankind Pharma Q1 FY27 results — review consolidated financials for Upakarma contribution.
Subsequent filings regarding operational efficiencies achieved post-acquisition.
Any further strategic announcements concerning the ayurvedic and nutraceutical portfolio.
LOW RISK
The acquisition involves an existing step-down subsidiary, completing full ownership, with minimal financial outlay relative to the parent company.
💡 Investor Takeaway
Mankind Lifesciences Private Limited acquired the remaining 10% stake in Upakarma Ayurveda Private Limited for ₹75 Lakhs cash, making it a 100% step-down subsidiary. Upakarma Ayurveda reported a turnover of ₹18.02 Crores for the year ended March 31, 2026.
⚖️ Strengths & Concerns
✅ Positives
- Full control over Upakarma Ayurveda (100% stake) allows for complete strategic alignment and operational synergy within the group.
- The acquisition strengthens Mankind Pharma's position in the Ayurvedic, herbal, and nutraceutical segments, as indicated by Upakarma's ₹18.02 Crores turnover in FY26.
⚠️ Concerns
- Upakarma Ayurveda's turnover decreased to ₹18.02 Crores in FY26 from ₹23.04 Crores in FY24, indicating a revenue decline over two years.
- The acquisition is classified as a Related Party Transaction, though stated to be at arm’s length with no promoter group interest in the target entity.
📅 Company Track Record
Mankind Pharma's subsidiary, Mankind Lifesciences Private Limited, previously held 90% stake in Upakarma Ayurveda. Upakarma became a step-down subsidiary on November 9, 2022. A past filing on March 18, 2026, indicated Mankind Pharma's acquisition of the Rivotril CNS brand from Roche, demonstrating active portfolio expansion.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What stake did Mankind Pharma's subsidiary acquire in Upakarma Ayurveda?
Mankind Lifesciences Private Limited, a wholly owned subsidiary of Mankind Pharma, acquired the remaining 10% stake in Upakarma Ayurveda Private Limited.
What was the cost of acquiring the remaining stake in Upakarma Ayurveda?
The remaining 10% stake in Upakarma Ayurveda was acquired for a cash consideration of ₹75 Lakhs, payable in two tranches.
What is Upakarma Ayurveda's turnover as of March 31, 2026?
Upakarma Ayurveda Private Limited reported a turnover of ₹18.02 Crores as on March 31, 2026.
What is the business of Upakarma Ayurveda?
Upakarma Ayurveda Private Limited is engaged in the business of trading/selling of ayurvedic, herbal and nutraceutical products.
When was Upakarma Ayurveda incorporated?
Upakarma Ayurveda Private Limited was incorporated on November 28, 2017.
Questions based on this BSE filing only. For information purposes.